The subsequent spatial analysis revealed that either CD8+ T cells or CD20+ B cells were more likely to be touching tumor cells in C1D1 and C2D8 samples from patients with a durable CBR compared with those from nonresponders (Figure 6E). The gene discussed is CD8A; the disease is neoplasm.